Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study

• Published in: OncoTargets and therapy Vol. 16; pp. 157 - 163
• Main Authors: Li, Guiling, Cheng, Mingxia, Hong, Kai, Jiang, Yao
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2023; Taylor & Francis Ltd; Dove
• Subjects: Anemia; Cancer; Cancer therapies; Care and treatment; Cervical cancer; Chemotherapy; Disease control; Drug therapy; Health aspects; Immunotherapy; Inhibitor drugs; Medical prognosis; Melanoma; Metastases; Metastasis; Monoclonal antibodies; Oncology, Experimental; Original Research; Paclitaxel; Patients; Prognosis; Response rates; Survival; Targeted cancer therapy; Toxicity; Tumors; China; toxicity; nab-paclitaxel; disease progression; apatinib; survival; camrelizumab
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S400376

Metastatic cervical cancer has a poor prognosis, and treatment options are limited. Immunotherapy has been used to achieve disease control in patients with cervical cancer; however, the efficacy of immunotherapy retreatment after disease progression is unclear. This study aimed to explore the efficacy and safety of immunotherapy retreatment in metastatic cervical cancer. We retrospectively reviewed the clinical data of patients with metastatic cervical cancer who underwent immunotherapy retreatment after disease progression following previous immunotherapy from June 2019 to April 2021. Fifteen patients were included in this study. All patients received combination immunotherapy retreatment consisting of camrelizumab, nab-paclitaxel, and apatinib. Four (26.7%) patients achieved partial response while three (20.0%) achieved stable disease. The objective response rate and disease control rate were 26.7% and 46.7%, respectively. The median progression-free survival and overall survival were 3.0 (95% confidence interval: 1.0-5.0) and 8.0 (95% confidence interval: 3.4-12.6) months, respectively. None of the patients discontinued treatment because of intolerable toxicity. Our findings suggest that the triplet combination immunotherapy retreatment could be a therapeutic option for patients with metastatic cervical cancer who failed initial immunotherapy.